Home / Research library / Vesugen
Vesugen: molecular data, studies & sources
Vesugen is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C15H26N4O8
- Molecular weight (MW)
- 390.39 g/mol
- PubChem compound ID
- 87571363
- Record title
- Lysyl-glutamyl-aspartic acid
This source structure is Lys-Glu-Asp (KED), the sequence identified as Vesugen in PMID 22808515. Terminal modifications, salts and counterions require separate specification.
Source: PubChem CID 87571363 · retrieved 2026-09-21 · Identity cross-reference

Chemical identifiers and source data
- IUPAC name
- (2S)-2-[[(2S)-4-carboxy-2-[[(2S)-2,6-diaminohexanoyl]amino]butanoyl]amino]butanedioic acid
- InChIKey
- LLSUNJYOSCOOEB-GUBZILKMSA-N
- SMILES
- C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N
Identifiers & sequence
- PubChem CID
- 87571363
- InChIKey
- LLSUNJYOSCOOEB-GUBZILKMSA-N
- Wikidata
- Q106027295
Peptide sequence · 3 residues (one-letter code; X marks a residue without a one-letter code)
KED
Condensed notation with terminal groups and non-standard residues
H-Lys-Glu-Asp-OH
Source: PubChem Biologic Line Notation. A reference sequence for the record, not an analysis of a supplied batch.
Calculated molecular descriptors
| Monoisotopic (exact) mass | 390.1751 Da |
|---|---|
| Heavy atoms | 27 |
| Hydrogen-bond donors | 7 |
| Hydrogen-bond acceptors | 7 |
| Rotatable bonds | 14 |
| Topological polar surface area | 222.1 Ų |
| Calculated logP (Crippen) | -2.16 |
| Rings | 0 |
| Stereocenters | 3 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
Registered clinical trials
Studies registered on ClinicalTrials.gov that list Vesugen as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
No registered study naming this compound was matched. This is a documented gap in registry coverage, not proof that no study exists.
Registry check 2026-10-01 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received Vesugen, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Research publication · design requires review
[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION].
Meshchaninov VN, Tkachenko EL, Zharkov SV et al. · Advances in gerontology = Uspekhi gerontologii · 2015
PMID 26390612
- Preclinical / laboratory research
Peptidegic stimulation of differentiation of pineal immune cells.
Linkova NS, Khavinson VKh, Chalisova NI et al. · Bulletin of experimental biology and medicine · 2011
PMID 22803057 · DOI: 10.1007/s10517-011-1470-1
- Preclinical / laboratory research
Peptides tissue-specifically stimulate cell differentiation during their aging.
Khavinson VKh, Linkova NS, Polyakova VO et al. · Bulletin of experimental biology and medicine · 2012
Experiments in cultured human-derived cells. Human cell culture is not a clinical trial in people.
PMID 22808515 · DOI: 10.1007/s10517-012-1664-1
- Preclinical / laboratory research
[Investigation of antihypoxic properties of short peptides].
Kozina LS · Advances in gerontology = Uspekhi gerontologii · 2008
PMID 18546825
- Preclinical / laboratory research
[Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging].
Khavinson VKh, Tarnovskaia SI, Lin'kova NS et al. · Advances in gerontology = Uspekhi gerontologii · 2014
PMID 25051766
Vesugen supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Vesugen for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Amino USAUSD | 20mg Vial1 recorded offers | 20mg Vial · $45.00Checked Oct 12, 2026Supplier listing, Vesugen 20mg Vial, Amino USA, opens in a new tab |
| Cenexa LabsUSD | 20mg Vial1 recorded offers | 20mg Vial · $64.99Checked Oct 12, 2026Supplier listing, Vesugen 20mg Vial, Cenexa Labs, opens in a new tab |
| American PeptidesUSD | 20mg Vial1 recorded offers | 20mg Vial · $60.00Recorded out of stock · Checked Oct 13, 2026Supplier listing, Vesugen 20mg Vial, American Peptides, opens in a new tab |
Reference sources & further reading
- PubChem compound record 87571363 — chemical identity and structure.
- Wikipedia: Vesugen — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Bronchogen
C18H30N4O9
446.5 g/mol · PubChem CID 11690869
6 selected publications · 0 human intervention studies
Cardiogen
Molecular identity needs further verification
1 selected publication · 0 human intervention studies
Cartalax
C12H19N3O8
333.29 g/mol · PubChem CID 87815447
0 selected publications · 0 human intervention studies
Chonluten
C11H17N3O8
319.27 g/mol · PubChem CID 194641
1 selected publication · 0 human intervention studies
Cortagen
C17H26N4O9
430.4 g/mol · PubChem CID 18439621
5 selected publications · 0 human intervention studies
Epithalon
C14H22N4O9
390.35 g/mol · PubChem CID 219042
4 selected publications · 1 human intervention study